Postby H is for Hawk » Tue Jan 19, 2016 7:59 pm
Here is an article from the 1/17/16 Philadelphia Inquirer newspaper about immunotherapy and its limitations. One disapointment - CART T-cell therapy, where the patient's immune cells are engineered to target the CD19 antigen; it does not appear to work for solid tumors. There was a lot of success with leukemia & lymphoma clinical trials using this approach in the last two years.
http://www.philly.com/philly/health/can ... ision.html
H is for Hawk (57)
10/14 L. hemi-colectomy 3 x 4 x 1 cm tumor, 13/14 lymph nodes pos. pT4a N2B M0 stage 3 MSS
11/14 - 4/15 12x FOLFOX
5/15 PET scan: 2.5 x 1.5 cm l. colon lesion, peri surface lesion SUV 2.4, adenocar., KRAS wd, BRAF V600E mut
6/15 HIPEC
9/15 Pleural lining & liver mets, CA 19-9: 6000
10/15 Vectibix Tafinlar Mekinist
11/15 1500
1/16 200
2/16 100, add Lentinan
3/16 122
6/16 4500
7/16 20,000, CT scan - three new liver mets
8/16 6700, FOLFIRI
9/16 4900, CT scan - two new liver mets
10/16 2255 vinorelbine